Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (Massachusetts General Hospital, b2f588)
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplantation is an investigational live biotherapeutic product being studied by Massachusetts General Hospital for the treatment of auto-brewery syndrome (ABS), also known as gut fermentation syndrome. [2, 7] The therapy aims to restore a healthy balance of gut bacteria by transferring fecal matter from a healthy donor into the patient's gastrointestinal tract. [3] In the clinical trial, this is being administered via oral capsules following a pre-treatment regimen of antibiotics and a colon cleanse to clear the existing gut microbiome. [5, 7] The study is designed as a pilot to assess the safety and feasibility of this approach for ABS, a condition where gut microbes ferment carbohydrates into ethanol, causing intoxication without alcohol consumption. [2, 3]
- Other names
- FMTfecal transplant
Beyond the preview
Go deeper on fecal microbiota transplant (Massachusetts General Hospital, b2f588).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (Massachusetts General Hospital, b2f588).